Roche and Zealand Pharma reported Phase 2 results for petrelintide showing mean weight loss of 10.7% (9.0% placebo‑adjusted) at 42 weeks and a favorable tolerability profile, but the efficacy missed analyst expectations and fell short of rival data from Eli Lilly’s amylin and GLP‑1 programs. Investors reacted sharply, sending Zealand shares down roughly 30% on the release. Analysts noted the drug’s apparent ceiling in dosing and concluded that the combination of modest incremental efficacy and a crowded obesity market may constrain petrelintide’s commercial prospects despite its tolerability. The readout underscores the competitive pressure in peptide weight‑loss therapeutics and the premium investors place on differentiated efficacy.